HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $42,861 | +6.2% | 1,122 | +0.3% | 0.00% | – |
| Q2 2023 | $40,363 | +71.6% | 1,119 | +81.7% | 0.00% | – |
| Q1 2023 | $23,526 | -23.3% | 616 | +14.3% | 0.00% | – |
| Q4 2022 | $30,669 | +53.3% | 539 | +5.3% | 0.00% | – |
| Q3 2022 | $20,000 | -13.0% | 512 | -2.1% | 0.00% | – |
| Q2 2022 | $23,000 | +15.0% | 523 | +2.8% | 0.00% | – |
| Q1 2022 | $20,000 | 0.0% | 509 | +1.8% | 0.00% | – |
| Q4 2021 | $20,000 | 0.0% | 500 | 0.0% | 0.00% | – |
| Q3 2021 | $20,000 | -13.0% | 500 | 0.0% | 0.00% | – |
| Q2 2021 | $23,000 | +9.5% | 500 | 0.0% | 0.00% | – |
| Q1 2021 | $21,000 | 0.0% | 500 | 0.0% | 0.00% | -100.0% |
| Q4 2020 | $21,000 | +61.5% | 500 | 0.0% | 0.00% | – |
| Q3 2020 | $13,000 | 0.0% | 500 | 0.0% | 0.00% | – |
| Q2 2020 | $13,000 | +44.4% | 500 | 0.0% | 0.00% | – |
| Q1 2020 | $9,000 | 0.0% | 500 | 0.0% | 0.00% | – |
| Q4 2019 | $9,000 | – | 500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 14,092,771 | $256,066,000 | 16.64% |
| BB BIOTECH AG | 8,247,860 | $149,864,000 | 3.97% |
| MSD Partners, L.P. | 2,245,000 | $40,792,000 | 3.07% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 428,633 | $5,969,000 | 2.84% |
| First Light Asset Management, LLC | 885,523 | $16,090,000 | 2.60% |
| SNYDER CAPITAL MANAGEMENT L P | 2,387,350 | $43,378,000 | 1.93% |
| Sterling Global Strategies LLC | 22,000 | $400,000 | 1.74% |
| Taylor Wealth Management Partners | 221,380 | $4,022,000 | 1.71% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,228,399 | $167,680,000 | 1.68% |
| DOHENY ASSET MANAGEMENT /CA | 124,393 | $2,260,000 | 1.18% |